Home

Life-changing therapies for rare disease and oncology patients

Pipeline

Rare Disease

ColiFin®

For Cystic Fibrosis Infections

Global ex-Europe rights (in-licensed from PARI Pharma GmbH)

Phase 3

Inhaled Murepavadin

For Cystic Fibrosis Infections

Funding by IMI and CF Foundation

Phase 1

EBX-002: Potentiated Inhaled Amikacin

For Non-tuberculous mycobacteria (NTM)

Preclinical

Lonodelestat (POL6014)

For Treatment of Cystic Fibrosis (Elastase Inhibitor)

Out-licensed to Santhera

Phase 1

Oncology

Balixafortide

Oncology / Non Oncology Orphan Indications

Readiness if initiated (under evaluation)

Phase 2

POL New CXCR4

Orphan Hematological Malignancies

Preclinical

AMR

OMPTA BamA / LptA Programs

AMR: WHO Priority 1 Pathogens

Funded by CARBX

Preclinical